NASDAQ
No price data available for this timeframe.
Lineage Cell Therapeutics, Inc. (LCTX) has a free cash flow growth of -63.02% as of Friday, May 29, 2026. This represents a 2299.21% decrease compared to its 12-month average of 2.87%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.